Novartis/Chiron: Validating the Value of Vaccine R&D
This article was originally published in RPM Report
Nothing solidifies the emergence of a hot investment sector like a big investment of cash, and Novartis AG provided that with its two-stage $5.7 billion close out of the remaining shares of Chiron Corp. that it did not already own (W#200510159). Novartis bought $300 million worth of Chiron's stock in December 2005 and then closed out the deal with $5.4 billion in April 2006.
You may also be interested in...
Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.
The vaccine business is made-to-order for Big Pharma. That's how Novartis is portraying the business to the financial community-a good growing environment if you can afford to reach scale. One of Novartis' partners in development, the Austrian firm Intercell, has also become a hot performer based on its strong piipeline of projects. Maybe there is room for both large and small.
Large investments by GlaxoSmithKline and Novartis in the US flu vaccine business highlight a rush back into the business. Government subsidies, technical assistance and market creation are making the flu vaccine field an attractive section of the pharma field again. It has been generally viewed for decades as a risky, difficult buisness with very little growth potential. Now the tables have turned.